American Pharmacists Association (APhA)
Trade associationSupport
Drug repurposing priority areas
Drug Repurposing for Unmet Medical Needs; Request for Information
FDA-2026-N-4492-0001RFI
Comments
608
Last activity Jul 13, 2026
Deadline
Closed on Jul 14, 2026
Closed Jul 14, 2026
Net supportiSupport minus oppose · campaigns included
+95%
+95% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Drug Repurposing for Unmet Medical Needs; Request for Information
- Posted
- May 12, 2026
- Comment period
- May 12, 2026 – Jul 14, 2026
- FR Doc
- 2026-09366
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
+95%
Net support
Support578Oppose2Other28
Aggregates include form-letter campaigns. Excluding them, net support is +95% across organic comments.
Who commented
Breakdown by commenter type.
Academic
20
Business
56
Individual
425
Trade association
8
Advocacy
59
Other
40
Comments over time
Weekly arrivals, stacked by stance.
Posted May 12, 2026Deadline Jul 14, 2026
May 11May 25Jun 8Jun 22Jul 6Jul 13
Support578Oppose2Other28
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
93%
0%
6%
Advocacy
100%
0%
0%
Business
100%
0%
0%
Other
95%
0%
5%
Academic
100%
0%
0%
Trade association
100%
0%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Drug repurposing for long covid82
Expand fda-approved indications65
Treatment for long covid64
Economic barriers to drug repurposing54
Incentives for drug repurposing43
Commercial and incentive barriers36
Ketamine for mental health33
Ketamine treatment efficacy29
Expanded clinical indications28
Patient access and affordability28
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Economic barriers to drug repurposing | Incentives for drug repurposing | Ai-driven drug repurposing technology | Commercial and incentive barriers | Drug repurposing priority areas |
|---|---|---|---|---|---|
American Pharmacists Association (APhA) Trade associationSupport The American Pharmacists Association (APhA) supports the FDA's drug repurposing efforts to accelerate patient access to | · | · | · | · | |
American Society of Transplant Surgeons Trade associationSupport The American Society of Transplant Surgeons (ASTS) supports the FDA's interest in drug repurposing to expand access to i | · | · | · | · | · |
AmoSey Inc. BusinessSupport AmoSey Inc., a Canadian life sciences advisory firm, supports the FDA's initiative on drug repurposing and provides spec | · | · | · | ||
Aspartes Pharmaceuticals, Inc. BusinessSupport Aspartes Pharmaceuticals, Inc. | · | · | · | · | |
AUTM Trade associationSupport AUTM, representing a group of university technology transfer offices and industry developers, supports the FDA's request | · | · | · | ||
Biostax Corp d/b/a Attune Biotech Inc. BusinessSupport Biostax Corp (Attune Biotech Inc.) submits a white paper supporting the FDA's initiative to modernize drug repurposing f | · | · | · | · | · |
Diagnostic Green LLC BusinessSupport Diagnostic Green LLC, representing Renew Pharmaceuticals Ltd., supports the FDA's initiative to solicit input on drug re | · | · | · | · | |
Main Street Foundation AdvocacySupport The Main Street Foundation's Center for Regulatory Analysis and Engagement (CRAE) supports the FDA's efforts to identify | · | · | · | · | · |
Muscular Dystrophy Association AdvocacySupport The Muscular Dystrophy Association (MDA) supports the FDA's initiative on drug repurposing, specifically advocating for | · | · | · | · | |
National Leiomyosarcoma Foundation AdvocacySupport The National Leiomyosarcoma Foundation (NLMSF) supports the FDA's initiative to explore drug repurposing for diseases wi | · | · | · | · | |
Nexus Concordat BusinessSupport Marjorie McCubbins, Founder of Nexus Concordat, submits a comment supporting the FDA's Request for Information on drug r | · | · | · | · | |
NuSirt Sciences, Inc. BusinessSupport Michael B. | · | · | · | · | · |
Pfizer Inc BusinessSupport Pfizer Inc. | · | · | · | · | |
Research!America AdvocacySupport Research!America, a nonprofit alliance, supports the FDA's Request for Information on drug repurposing for unmet medical | · | · | · | · | |
Sen-Jam Pharmaceutical BusinessSupport Sen-Jam Pharmaceutical supports the FDA's drug repurposing RFI but recommends expanding the scope to include a mechanist | · | · | · | · | |
Single Dose Therapeutics, Inc. BusinessSupport Single Dose Therapeutics, Inc., an early-stage biotechnology company, supports the FDA's interest in drug repurposing to | · | · | · | ||
The RWE Alliance Trade associationSupport The RWE Alliance, a coalition of real-world data and analytics organizations, supports the FDA's efforts to identify dru | · | · | · | · |
American Society of Transplant Surgeons
Trade associationSupport
AmoSey Inc.
BusinessSupport
Economic barriers to drug repurposing
Incentives for drug repurposing
Aspartes Pharmaceuticals, Inc.
BusinessSupport
Incentives for drug repurposing
AUTM
Trade associationSupport
Incentives for drug repurposing
Commercial and incentive barriers
Biostax Corp d/b/a Attune Biotech Inc.
BusinessSupport
Diagnostic Green LLC
BusinessSupport
Commercial and incentive barriers
Main Street Foundation
AdvocacySupport
Muscular Dystrophy Association
AdvocacySupport
Economic barriers to drug repurposing
National Leiomyosarcoma Foundation
AdvocacySupport
Drug repurposing priority areas
Nexus Concordat
BusinessSupport
Ai-driven drug repurposing technology
NuSirt Sciences, Inc.
BusinessSupport
Pfizer Inc
BusinessSupport
Economic barriers to drug repurposing
Research!America
AdvocacySupport
Economic barriers to drug repurposing
Sen-Jam Pharmaceutical
BusinessSupport
Economic barriers to drug repurposing
Single Dose Therapeutics, Inc.
BusinessSupport
Economic barriers to drug repurposing
Incentives for drug repurposing
The RWE Alliance
Trade associationSupport
Ai-driven drug repurposing technology
21 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jul 13, 2026Comment from Melissa KlecknerSupportIndividual
An infusion nurse who treats patients with major depressive disorder argues in favor of repurposing generic racemic ketamine for the treatment of major depressive disorder. The commenter highlights the high efficacy and rapid symptom relief of ketamine compared to traditional antidepressants for treatment-resistant patients.
Read comment → - Jul 10, 2026Comment from Sara MolinaroSupportIndividualRead comment →
- Jun 23, 2026Comment from Shaare NefeshSupportAcademic
Dr. Sinai Oren, Director of Sha'arei Nefesh Clinic, advocates for a regulatory shift to recognize ketamine as a "Psychotherapeutic Catalyst" rather than just a symptom-based pharmaceutical. He proposes a framework where ketamine is used as an adjunct to licensed psychotherapy to enhance neuroplasticity and cognitive reframing in treatment-resistant cases.
Read comment → - Jun 11, 2026Comment from Vie Sante MedicalSupportBusiness📎 Attachment
Vie Santé Medical, a healthcare provider, supports the inclusion of racemic ketamine in the FDA's drug repurposing initiative for unmet medical needs. They argue that ketamine has a strong evidence base for treating treatment-resistant depression and chronic pain, but lacks commercial incentive for manufacturers to seek formal approval.
Read comment → - Jun 11, 2026Comment from Regina SaylorSupportIndividual📎 Attachment
A board-certified physician with clinical experience in treating depression with IV ketamine argues that IV ketamine is a compelling candidate for drug repurposing. The commenter highlights the drug's efficacy for treatment-resistant depression and emphasizes that FDA recognition would improve patient access by facilitating insurance coverage and reducing financial barriers.
Read comment → - Jun 11, 2026Comment from Tiffany FrankeSupportBusiness📎 Attachment
Tiffany Franke, Co-Founder of Ember Health, urges the FDA to prioritize the evaluation of intravenous (IV) ketamine for Major Depressive Disorder (MDD). She argues that IV ketamine is an effective treatment for treatment-resistant depression and that formal FDA recognition would improve patient access, safety standards, and insurance coverage.
Read comment → - Jun 11, 2026Comment from Juliet StantonSupportIndividual📎 Attachment
A patient with treatment-resistant depression argues that the FDA should evaluate IV ketamine for drug repurposing to treat severe depressive illness. The commenter shares their personal success with the treatment and emphasizes that FDA approval would help overcome insurance barriers and make the life-saving treatment more affordable and accessible to others.
Read comment → - Jun 11, 2026Comment from Ginger CloudSupportIndividual📎 Attachment
Ginger Cloud, a licensed mental health counselor and ketamine-assisted psychotherapist, urges the FDA to prioritize ketamine for drug repurposing to treat mental health conditions. She argues that the existing scientific evidence for its efficacy in treatment-resistant depression warrants a new indication to improve patient access and insurance coverage.
Read comment → - Jun 11, 2026Comment from Daniel MulcahySupportIndividual📎 Attachment
A 100% VA-disabled veteran argues in favor of expediting the recognition of ketamine's value for treating long-term pain and treatment-resistant depression. The commenter provides personal testimony and a detailed research appendix to support the safety and efficacy of ketamine in a clinical setting compared to recreational use.
Read comment → - Jun 11, 2026Comment from AnonymousSupportIndividualRead comment →